

BME - GROWTH

Palacio de la Bolsa
Plaza de la Lealtad, 1
28014 Madrid

Alicante, 10th October 2023

COMMUNICATION- OTHER RELEVANT INFORMATION - FACEPHI BIOMETRIA, S.A.

Dear Sirs,

Under the provisions of article 17 of the Regulation (EU) No. 596/2014 on market abuse, and article 227 of the Law 6/2023 17th March, Spanish Securities Market and Investment Services, and related provisions, as well as in the Circular 3/2020 of BME Growth, we inform you about the following information related to the company FACEPHI BIOMETRIA, S.A. (hereinafter “FacePhi” or “the Company”, interchangeably).

The Company published last 21st July the resolutions adopted by the Extraordinary General Shareholders’ Meeting held on that date, which included, as the first point, the delegation to the Board of Directors of the power to issue notes convertible into shares of the Company in favour of Nice & Green, S.A. (“Nice & Green”), with the exclusion of pre-emptive subscription rights, for a maximum conversion amount of €20,000,000, as well as to increase de share capital by the amount necessary to cover the conversion of said notes.

The same day, 21st July, the Board of Directors adopted a resolution, under that said delegation, to carry out the issue of 500 convertible notes for a maximum conversion amount of € 5,000,000 (the “Convertible Notes JULY 2023), with Nice & Green being the sole subscriber of that issuance.

Nice&Green, on 5th October, under the provisions of the investment agreement, notified to the Company and exercised its right to convert 220 Notes (July 2023) for a conversion amount of 2,200,000 euros. Following this conversion, the Tranche July 2023 Convertible Notes is extinguished.

As a result of the foregoing, the Company will grant a capital increase title deed to cover the conversion of that said Notes. The new shares of the Company (1,293,889 shares) are issued with an issuing price of 1,7003 euros (issue premium 1,6603 euros plus 0.04 euros of nominal value).

After the aforementioned capital increase has been granted, the share capital will set at the sum of € 821,282.56, represented by 20,532,064 shares of € 0.04 nominal value each, of the same class, equal, cumulative and indivisible.

In compliance with Circular 3/2020 of the segment BME Growth of BME MTF Equity, it is expressly stated that the information hereby communicated has been produced under the sole responsibility of the company and its administrators.

We remain at your disposal for any clarification you might deem necessary.

Sincerely,

Javier Mira Miró

Chairman of the Board of Directors